Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Goura K. Rath is active.

Publication


Featured researches published by Goura K. Rath.


International Journal of Radiation Oncology Biology Physics | 1996

IMPROVING CANCER RADIOTHERAPY WITH 2-DEOXY-D-GLUCOSE: PHASE I/II CLINICAL TRIALS ON HUMAN CEREBRAL GLIOMAS

Bidhu Kalyan Mohanti; Goura K. Rath; Naranappa Anantha; V. Kannan; B. S. Das; Bangalore A. Chandramouli; Ajit K. Banerjee; Sarala Das; Amarnath Jena; Ramamurthy Ravichandran; Uday P. Sahi; Rajinder Kumar; Neeru Kapoor; Vijay K. Kalia; B. S. Dwarakanath; Viney Jain

PURPOSE Evaluation of tolerance, toxicity, and feasibility of combining large fraction (5 Gy) radiotherapy with 2-deoxy-D-glucose (2DG), an inhibitor of glucose transport and glycolysis, which has been shown to differentially inhibit repair of radiation damage in cancer cells. METHODS AND MATERIALS Twenty patients with supratentorial glioma (Grade 3/4), following surgery were treated with four weekly fractions of oral 2DG (200 mg/kg body weight) followed by whole brain irradiation (5 Gy). Two weeks later, supplement focal radiation to the tumor (14 Gy/7 fractions) was given. Routine clinical evaluation, x-ray computerized tomography (CT), and magnetic resonance (MR) imaging were carried out to study the acute and late radiation effects. RESULTS All the 20 patients completed the treatment without any interruption. The vital parameters were within normal limits during the treatment. None reported headache during the treatment. Mild to moderate nausea and vomiting were observed during the days of combined therapy (2DG + RT) in 10 patients. No significant deterioration of the neurological status was observed during the treatment period. Seven patients were alive at 63, 43, 36, 28, 27, 19, and 18 months of follow-up. In these patients, the clinical and MR imaging studies did not reveal any late radiation effects. CONCLUSIONS Feasibility of administering the treatment (2DG + 5 Gy) is demonstrated by the excellent tolerance observed in all 20 patients. Further, the clinical and MR studies also show the absence of any brain parenchymal damage.


Lancet Oncology | 2014

The growing burden of cancer in India: epidemiology and social context.

Mohandas K. Mallath; David G Taylor; Rajendra A. Badwe; Goura K. Rath; Viswanathan Shanta; C.S. Pramesh; Raghunadharao Digumarti; Paul Sebastian; Bibhuti B Borthakur; Ashok Kalwar; Sanjay Kapoor; Shaleen Kumar; Jennifer L. Gill; Moni Abraham Kuriakose; Hemant Malhotra; Suresh C. Sharma; Shilin Shukla; Lokesh Viswanath; Raju Titus Chacko; Jeremy Pautu; Kenipakapatnam S Reddy; Kailash S Sharma; Arnie Purushotham; Richard Sullivan

Cancer can have profound social and economic consequences for people in India, often leading to family impoverishment and societal inequity. Reported age-adjusted incidence rates for cancer are still quite low in the demographically young country. Slightly more than 1 million new cases of cancer are diagnosed every year in a population of 1.2 billion. In age-adjusted terms this represents a combined male and female incidence of about a quarter of that recorded in western Europe. However, an estimated 600,000-700,000 deaths in India were caused by cancer in 2012. In age-standardised terms this figure is close to the mortality burden seen in high-income countries. Such figures are partly indicative of low rates of early-stage detection and poor treatment outcomes. Many cancer cases in India are associated with tobacco use, infections, and other avoidable causes. Social factors, especially inequalities, are major determinants of Indias cancer burden, with poorer people more likely to die from cancer before the age of 70 years than those who are more affluent. In this first of three papers, we examine the complex epidemiology of cancer, the future burden, and the dominant sociopolitical themes relating to cancer in India.


Radiotherapy and Oncology | 1995

Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis

Biswa Mohan Biswal; Punita Lal; Goura K. Rath; Nootan Kumar Shukla; Bidhu Kalyan Mohanti; Sv Suryanarayana Deo

Haemorrhagic radiation proctitis (HRP) is infrequently seen amongst the patients who are either undergoing or have undergone radiotherapy to the pelvis. We treated 16 documented cases of HRP, who did not respond to conventional steroid retention enemas, with 4% formalin application. It was observed that the rectal bleeding was controlled completely in 81% cases in median follow up of 11 months (range 6-17 months) and diversion colostomy could be avoided in all the cases. The effectiveness of local formalin application in severe HRP is described in this article.


Indian Journal of Cancer | 2005

Clinical features and prognostic factors of early breast cancer at a major cancer center in North India

Vinod Raina; Manisha Bhutani; Rajeev Bedi; Atul Sharma; Sv Suryanarayana Deo; Nootan Kumar Shukla; Bidhu Kalyan Mohanti; Goura K. Rath

BACKGROUND Data on the clinical profile of early breast cancer (EBC) from India is scant. Due to differences in genetics, environment, lifestyle, socio-demographic structure and ethnicity, the presentation and behavior of breast cancer in India may be different. AIMS To analyze the clinical presentation and outcome of EBC patients. SETTINGS AND DESIGN A single center retrospective study. MATERIALS AND METHODS Data from 487 EBC patients registered and treated at our institute from 1993 through 1999 were analyzed. Coxs multivariate regression test was used to determine prognostic factors for overall and disease-free survival (OS & DFS). RESULTS The median age was 47 years and 49.7% patients were pre-menopausal. Ninety-six per cent patients presented with a lump. Stages I, IIa, and IIb comprised 7.8%, 38.8%, and 47.6% respectively. Only 11.3% patients opted for breast-conserving surgery (BCS) while the remaining 88.7% underwent modified radical mastectomy (MRM). Adjuvant chemotherapy was administered to 275 (56.5%), and radiotherapy to 146 (29.9%). Estrogen receptor status was known in 173, of whom 93 (53.7%) were positive. Most patients were prescribed Tamoxifen for 5 years. At a median follow-up of 48 months, 126 (25.9%) patients had relapsed (systemic 107, loco-regional 19) and 94 (19.3%) had died. Five-year DFS and OS were 73% and 78%, respectively. On multivariate analysis, four positive nodes adversely influenced survival (P< 0.01). CONCLUSIONS The median age at presentation was 47 years, significantly lower than most Western figures. The majority (86.4%) had a lump size > two cm. BCS was done in only 11% and the rest underwent MRM. Nodal involvement was the significant prognostic factor.


Lancet Oncology | 2014

Delivery of affordable and equitable cancer care in India

C.S. Pramesh; Rajendra A. Badwe; Bibhuti B Borthakur; Madhu Chandra; Elluswami Hemanth Raj; T Kannan; Ashok Kalwar; Sanjay Kapoor; Hemant Malhotra; Sukdev Nayak; Goura K. Rath; T G Sagar; Paul Sebastian; Rajiv Sarin; Viswanathan Shanta; Suresh C. Sharma; Shilin Shukla; Manavalan Vijayakumar; D K Vijaykumar; Ajay Aggarwal; Arnie Purushotham; Richard Sullivan

The delivery of affordable and equitable cancer care is one of Indias greatest public health challenges. Public expenditure on cancer in India remains below US


Journal of Neuro-oncology | 1994

Management of intracranial metastases of differentiated carcinoma of thyroid

Biswa Mohan Biswal; Chandra Sekhar Bal; Manavjit Sandhu; Padhy Ak; Goura K. Rath

10 per person (compared with more than US


Pediatric Blood & Cancer | 2006

Hodgkin's disease in Indian children: Outcome with chemotherapy alone

L. S. Arya; Veronique Dinand; Vasantha Thavaraj; Sameer Bakhshi; Ramesh Dawar; Goura K. Rath; Rajvir Singh; Tribhuvan S. Vats

100 per person in high-income countries), and overall public expenditure on health care is still only slightly above 1% of gross domestic product. Out-of-pocket payments, which account for more than three-quarters of cancer expenditures in India, are one of the greatest threats to patients and families, and a cancer diagnosis is increasingly responsible for catastrophic expenditures that negatively affect not only the patient but also the welfare and education of several generations of their family. We explore the complex nature of cancer care systems across India, from state to government levels, and address the crucial issues of infrastructure, manpower shortages, and the pressing need to develop cross-state solutions to prevention and early detection of cancer, in addition to governance of the largely unregulated private sector and the cost of new technologies and drugs. We discuss the role of public insurance schemes, the need to develop new political mandates and authority to set priorities, the necessity to greatly improve the quality of care, and the drive to understand and deliver cost-effective cancer care programmes.


Quality of Life Research | 1999

Temporal assessment of quality of life of head and neck cancer patients receiving radical radiotherapy

S. Chawla; Bidhu Kalyan Mohanti; M. Rakshak; S. Saxena; Goura K. Rath; S. Bahadur

SummaryBrain metastases in differentiated carinoma of the thyroid is a rare occurrence. We treated five documented cases of carcinoma of thyroid with brain metastases out of 400 cases of thyroid cancer treated between 1972 to 1993. 4 were females out of which one was pregnant during the appearance of brain metastases. All cases were treated with thyroidectomy, and radioiodine as primary therapy. Brain metastases developed 6 months to 11 years following treatment of the primary and were treated with radiotherapy and suppressive levothyroxine. We observed the beneficial effect of suppressive thyroxine and the poor prognosis associated with pregnancy and withdrawl of thyroid replacement therapy. 3 of the 5 patients are alive 12–23 months after treatment for brain metastases, while 2 patients died at 4 months and 7 years post brain metastases due to pulmonary and hepatic failure, respectively.


Lancet Oncology | 2014

Cancer research in India: national priorities, global results

Richard Sullivan; Rajendra A. Badwe; Goura K. Rath; C.S. Pramesh; Viswanathan Shanta; Raghunadharao Digumarti; Anil D'Cruz; Suresh C. Sharma; Lokesh Viswanath; Arun Shet; Manavalan Vijayakumar; Grant Lewison; Mammen Chandy; Priyadarshini Kulkarni; M R Bardia; Shaleen Kumar; Rajiv Sarin; Paul Sebastian; Preet K. Dhillon; Preetha Rajaraman; Edward L. Trimble; Ajay Aggarwal; D K Vijaykumar; Arnie Purushotham

To assess the efficacy of chemotherapy alone, using four cycles of COPP alternating with four cycles of ABVD in all stages of childhood Hodgkins disease (HD).


Asian Pacific Journal of Cancer Prevention | 2015

Radiation Induced Lung Injury: Prediction, Assessment and Management

Prashanth Giridhar; Supriya Mallick; Goura K. Rath; Pramod Kumar Julka

The study was undertaken to evaluate physical, psychological and functional aspects in quality of life (QoL) assessment prospectively in biopsy-proven head and neck cancer patients receiving radical radiotherapy. Fifty male patients were assessed using Karnofskys Performance Status (KPS), Becks Depression Inventory (BDI) and the Functional Living Index – Cancer (FLIC). Patient questionnaires were completed before radiotherapy, during 3–4 weeks of radiotherapy and 3 months after radiotherapy. Before the start of radiotherapy, KPS was 91±10.26, FLIC was 129.98±33.41 and BDI was 7.10±4.57. This indicated good performance and functional status with lower depression. In weeks 3–4 of radiotherapy, KPS (71.00±20.12) and FLIC (81.34±45.23) decreased, while BDI(16.56 ±9.01) increased, indicating impairment in QoL. Three months after radiotherapy, KPS (78.37±23.0), FLIC (119.51± 43.62) and BDI(9.02±7.81) improved but were not restored to pre-treatment levels. When patients were scheduled for radical radiotherapy, maximum deterioration in QoL was seen in weeks 3–4. This is the time when maximum supportive care and psychologic counselling is required.

Collaboration


Dive into the Goura K. Rath's collaboration.

Top Co-Authors

Avatar

Pramod Kumar Julka

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Bidhu Kalyan Mohanti

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Daya Nand Sharma

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Supriya Mallick

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Nootan Kumar Shukla

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Dayanand Sharma

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Tarun Puri

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Kunhi Parambath Haresh

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

R. C. Joshi

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Rony Benson

All India Institute of Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge